Table 3

Morbidity and mortality outcomes with administration of recombinant FVIIa

PrematchingPostmatching, all comersPostmatching, primary TBI
−FVII (%)+FVII (%)ORP value or 95% CI−FVII (%)+FVII (%)ORP value or 95% CI−FVII (%)+FVII (%)ORP value or 95% CI
Mortality18.943.23.3*2.15 to 4.9322.930.61.50.69 to 3.2121.620.00.90.24 to 3.48
 +Craniectomy23.140.52.3*1.20 to 4.3028.627.30.90.28 to 3.0822.216.70.70.08 to 6.22
 −Craniectomy17.745.33.9*2.22 to 6.6819.733.32.00.74 to 5.6621.425.01.20.19 to 7.68
Morbidity23.619.00.80.45 to 1.2733.322.50.60.26 to 1.2817.121.11.30.31 to 5.28
 VAP12.59.50.70.37 to 1.4719.810.20.50.16 to 1.322.90
 ARDS4.63.20.70.21 to 2.192.16.13.10.50 to 18.9900
 DVT3.62.10.60.14 to 2.376.32.00.30.04 to 2.675.70
 Meningitis0.81.11.30.17 to 9.424.22.00.50.05 to 4.4100
 Abscess0.32.18.0*1.71 to 37.640000
 CRBSI2.61.10.40.06 to 2.946.3000
  • *P<0.05.

  • ARDS, acute respiratory distress syndrome; CRBSI, catheter-related blood stream infection; DVT, deep vein thrombosis; FVII, recombinant factor VIIa; TBI, traumatic brain injury; VAP, ventilator-associated pneumonia.